OncoSec Medical to Present at Three Events in January
January 07 2015 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing
DNA-based intratumoral cancer immunotherapies, will present at
three events in January. The Company’s agenda includes a number of
high-profile scientific and investment conferences.
Biotech Showcase 2015
Punit Dhillon, President and CEO, will present a corporate
overview of the Company at Biotech Showcase 2015, taking place
January 12-14, 2015 in San Francisco, CA. The presentation is
scheduled to begin at 9:00 AM PT on Tuesday, January 13.
At the time of the presentation, a live webcast will be
available via the following link:
http://edge.media-server.com/m/p/y67x6cc4.
OncoSec recommends registering at least 10 minutes prior to the
start of the presentation to ensure timely access. After the
presentation, an archived version of the webcast will be available
for 90 days in the “Events” section of the OncoSec web page at
http://www.oncosec.com.
Biotech Showcase™ provides biotechnology and life sciences
companies with an opportunity to present to and meet with investors
and pharmaceutical executives during the course of one of the
industry's largest annual healthcare investor conferences. The
program includes lunch plenary sessions featuring top industry
leaders and innovators speaking on industry- and time-relevant
topics, as well as presentations from both private and public
companies. For more information, please visit:
http://www.ebdgroup.com/bts/index.php
An Introspective on Immunotherapy
OncoSec Medical will host “An Introspective on Immunotherapy: A
Symposium on Intratumoral Therapy” on Tuesday, January 13 at the
Palace Hotel in San Francisco, CA at 5:00 PM PT. The symposium will
feature several key opinion leaders discussing the rationale and
potential of intratumoral immunotherapy, and OncoSec’s role as a
leader in this field.
After the symposium has concluded, a webcast will be made
available via the following link:
www.oncosec.com/jmp-immunotherapy-symposium-2015/
For more information or to RSVP, please contact Jordyn Kopin,
Associate Director of Corporate Communications:
jkopin@oncosec.com
Noble Financial Capital Markets 11th Annual Investor
Conference
Jordyn Kopin, Associate Director of Corporate Communications,
will present a corporate overview of the Company at Noble Financial
Capital Markets’ 11th Annual Investor Conference. The conference
will be held January 18-21, 2015 at Club Med, Sandpiper Bay, FL.
For more information, please visit:
http://www.nobleresearch.com/D2/2015.htm
About OncoSec Medical
OncoSec Medical Inc. is a biopharmaceutical company developing
its investigational ImmunoPulse intratumoral cancer immunotherapy.
OncoSec Medical's core technology is designed to
enhance the local delivery and uptake of DNA IL-12 and
other DNA-based immune-targeting agents. Clinical studies of
ImmunoPulse have demonstrated an acceptable safety profile and
preliminary evidence of anti-tumor activity in the treatment of
various skin cancers, as well as the potential to initiate a
systemic immune response without the systemic toxicities associated
with other treatments. OncoSec's lead program evaluating
ImmunoPulse for the treatment of metastatic melanoma is currently
in Phase 2 development, and is being conducted in collaboration
with several prominent academic medical centers. As the company
continues to evaluate ImmunoPulse in its current indications, it is
also focused on identifying and developing new immune-targeting
agents, investigating additional tumor indications, and evaluating
combination-based immunotherapy approaches. For more information,
please visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Jordyn Kopin,
855-662-6732investors@oncosec.comorPublic Relations:Dian Griesel
Int’l.Laura Radocaj, 212-825-3210lradocaj@dgicomm.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Aug 2024 to Sep 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Sep 2023 to Sep 2024